Will Unum’s approach take the CAR T cell therapy market by storm?
Cell therapy is one of the hottest topics in cancer immunotherapy; however, it remains a field still in it’s infancy as companies and researchers work on strategies and concepts to increase efficacy and overcome resistance. The strategic landscape is still being defined. In cell therapy the ultimate winner may not be the company that is first to market.
Drs Seth Ettenberg and Michael Vasconcelles, Unum at #ASH15
In this post, we’re continuing this week’s theme of posts around novel cell therapies. Unum Therapeutics is a company that is no doubt already on your radar if you are into CAR-T cells.
Back at ASH 2015, I had the pleasure of interviewing Dr Seth Ettenberg (CSO) on the left and Dr Michael Vasconcelles (CMO) on the right.
We talked about what differentiates their approach from others in the CAR T cell space.
Subscribers can log in.
This content is restricted to subscribers
Posted by MaverickNY
This content is restricted to subscribers